Department of Medicine

kidney x-ray

VU study shows common diabetes drug can slow chronic kidney disease progression

Vanderbilt investigators have demonstrated in two studies that metformin-based treatments delay the onset and progression of chronic kidney disease (CKD) compared with other treatments for diabetes.

Insulin in vials

Study tracks insulin’s risks as second-line diabetes medication

In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.

Roden named to NIH’s genomics advisory council

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH).

Rising tobacco epidemic in Asia linked to elevated risk of death

A new study estimates that tobacco smoking has been linked to approximately 2 million deaths among adult men and women in Asia in recent years and predicts a rising death toll.

New center dedicated to kidney disease

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.

Heart illustration thumbnail

Normalizing calcium flux to treat atrial fibrillation

A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation.

1 97 98 99 100 101 117